Tenderwize
Retour à la recherche

Open-House Biologics Discount Agreements 2026-13 - Romiplostim

Techniker Krankenkasse·Hamburg, Germany·Deadline Jun 29, 2028 · 673 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-13 - Romiplostim

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

15 / 100

Facteurs de risque

The agreement does not guarantee any sales volume; actual demand depends on prescription behavior and competition from...

This is not a public procurement; legal remedies lie with social courts, not procurement chambers. Different rules appl...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jun 2028
  • Supply of pharmaceutical products containing Romiplostim.
  • Conclusion of discount agreements with health insurance funds (Techniker Krankenkasse, HEK, hkk).
Afficher le résumé complet

This is an Open-House procedure to conclude discount agreements (Rabattverträge) for the active substance Romiplostim under §130a SGB V. All eligible pharmaceutical entrepreneurs can join at any time during the contract period (up to 24 months). No exclusivity is granted, and no guaranteed volume. The procedure is not a public procurement according to EU directives; legal disputes go to social courts.

Risques

The agreement does not guarantee any sales volume; actual demand depends on prescription behavior and competition from...

This is not a public procurement; legal remedies lie with social courts, not procurement chambers. Different rules appl...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of §4(18) AMG with valid marketing authorization for Romiplostim.
  • Must have seat in Germany, EU, or EEA.

Administrative

  • Must submit a self-declaration on admission and reliability (Anlage 4).

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House Biologics Discount Agreements 2026-13 - Romiplostim

Conclusion of drug discount agreements for Romiplostim with eligible pharmaceutical entrepreneurs under an Open-House procedure.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jun 2026 - Jun 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Jun 29, 2028

Détails de la procédure

Date de publication
07 May 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
318965-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3